Target expression is a relevant factor in synthetic lethal screens

por Schultz, Iman J., Coelingh Bennink, Herjan J. T.
Publicado 2022

Treatment of Serious COVID-19 with Testosterone Suppression and High-dose Estrogen Therapy

por Coelingh Bennink, Herjan J.T., Foidart, Jean-Michel, Debruyne, Frans M.J.
Publicado 2021

Reply to Bexultan Kazybay and Yingqiu Xie’s Letter to the Editor re: Herjan J.T. Coelingh Bennink, Jean-Michel Foidart, Frans M.J. Debruyne. Treatment of Serious COVID-19 with Test...

por Coelingh Bennink, Herjan J.T., Foidart, Jean-Michel, Debruyne, Frans M.J.
Publicado 2021

Testosterone suppression combined with high dose estrogen as potential treatment of SARS-CoV-2. A mini review

por Coelingh Bennink, Herjan J.T., Egberts, Jan F.M., Debruyne, Frans M.J.
Publicado 2022

Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives

por Mawet, Marie, Maillard, Catherine, Klipping, Christine, Zimmerman, Yvette, Foidart, Jean-Michel, Coelingh Bennink, Herjan J.T.
Publicado 2015

Tumor suppression, dose-limiting toxicity and wellbeing with the fetal estrogen estetrol in patients with advanced breast cancer

por Schmidt, Marcus, Lenhard, Hans, Hoenig, Arnd, Zimmerman, Yvette, Krijgh, Jan, Jansen, Monique, Coelingh Bennink, Herjan J. T.
Publicado 2020

A multicenter, randomized, placebo-controlled study to select the minimum effective dose of estetrol in postmenopausal participants (E4Relief): part 2—vaginal cytology, genitourina...

por Gaspard, Ulysse, Taziaux, Mélanie, Jost, Maud, Coelingh Bennink, Herjan J.T., Utian, Wulf H., Lobo, Rogerio A., Foidart, Jean-Michel
Publicado 2023

Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: Results of a phase II dose-finding pilot study

por Duijkers, Ingrid J.M., Klipping, Christine, Zimmerman, Yvette, Appels, Nicole, Jost, Maud, Maillard, Catherine, Mawet, Marie, Foidart, Jean-Michel, Coelingh Bennink, Herjan J. T.
Publicado 2015

A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1. Vasomotor symptoms and overall safety

por Gaspard, Ulysse, Taziaux, Mélanie, Mawet, Marie, Jost, Maud, Gordenne, Valérie, Coelingh Bennink, Herjan J.T., Lobo, Rogerio A., Utian, Wulf H., Foidart, Jean-Michel
Publicado 2020

Progesterone from ovulatory menstrual cycles is an important cause of breast cancer

por Coelingh Bennink, Herjan J. T., Schultz, Iman J., Schmidt, Marcus, Jordan, V. Craig, Briggs, Paula, Egberts, Jan F. M., Gemzell-Danielsson, Kristina, Kiesel, Ludwig, Kluivers, Kirsten, Krijgh, Jan, Simoncini, Tommaso, Stanczyk, Frank Z., Langer, Robert D.
Publicado 2023

Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review

por Coelingh Bennink, Herjan J T, Krijgh, Jan, Egberts, Jan F M, Slootweg, Maria, van Melick, Harm H E, Roos, Erik P M, Somford, Diederik M, Zimmerman, Yvette, Schultz, Iman J, Clarke, Noel W, van Moorselaar, R Jeroen A, Debruyne, Frans M J
Publicado 2022

Estetrol Prevents Hot Flushes and Improves Quality of Life in Patients with Advanced Prostate Cancer Treated with Androgen Deprivation Therapy: The PCombi Study

por Zimmerman, Yvette, Frydenberg, Mark, van Poppel, Hendrik, van Moorselaar, R. Jeroen A., Roos, Erik P.M., Somford, Diederik M., Roeleveld, Ton A., de Haan, Tjard D., van Melick, Harm H.E., Reisman, Yacov, Krijgh, Jan, Debruyne, Frans M.J., Coelingh Bennink, Herjan J.T.
Publicado 2022

Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)

por Coelingh Bennink, Herjan J.T., van Moorselaar, Jeroen A., Crawford, E. David, Roos, Erik P.M., Somford, Diederik M., Roeleveld, Ton A., de Haan, Tjard D., van Melick, Harm H.E., Reisman, Yacov, Zimmerman, Yvette, van Osta, Gonnie, Krijgh, Jan, Shore, Neal D., Saad, Fred, Schally, Andrew V., Debruyne, Frans M.J.
Publicado 2021